Cannabis just moved from Schedule I to Schedule III — and the biggest implications have nothing to do with lifestyle or politics.
In this episode of Market Outsiders, Jenny Rae and Namaan break down what reclassification means for the market: who benefits, who loses, and why cannabis stocks dropped on “good” news.
They unpack the real unlocks behind the headlines — Medicare and Medicaid eligibility, federally funded research, banking access, and why Big Pharma, consumer giants, and even beer companies may now have the edge.
This is a regulatory shock case study: how one policy change reshapes competition, pricing power, supply chains, and long-term winners across healthcare and consumer markets.
Partner Links:
- Learn more about NordStellar's Threat Exposure Management Program; unlock 10% off with code SIMPLIFIED-10
Chapters:
- 01:05 — What Cannabis Reclassification Actually Changes
- 03:15 — Schedule I vs Schedule III: Why It Matters
- 05:45 — Banking, Taxes, and the Industry’s Hidden Constraints
- 08:20 — Medicare, Medicaid, and the Real Demand Unlock
- 11:10 — Why Cannabis Stocks Fell on “Good” News
- 13:30 — Big Pharma, Big Beer, and New Market Entrants
- 19:40 — Supply Chains, Compliance, and Rising Costs
- 25:00 — Who Wins, Who Loses, and What Comes Next